| Source of record | UK Co-ordinating Committee on Cancer Research (UKCCCR) |
| Serial number at source | BNLI STANFORD V |
| Title of trial | A Randomised Phase III Study of the Stanford V Regimen Compared with ABVD for the Treatment of Advanced Hodgkins Disease |
| Disease or condition | Breast |
| Current status of trial | Open |
| Objectives | To compare in a multicentre trial Stanford V with ABVD in patients with advanced Hodgkin's disease using relapse free survival as the primary endpoint. |
| Eligibility criteria | 1. Histologically confirmed Hodgkin's disease
2. Clinical Stage IB, IIB, IIIA, IIIB or IV OR clinial stage Ia or IIA with locally extensive disease
3. Aged 18-60 years
4. No previous history of malignant disease except basal cell or squamous cell carcinoma of the skin
5. Normal values for FBC, hepatic and renal function
6. Written informed consent
7. Patients must be assessed by the treating medical oncologist/ haematologist and radiation oncologist together prior to entry into the study.
8. No previous therapy for Hodgkin's disease
9. No clinical evidence of HIV infection
10. No pre-existing cardiac or pulmonary disease |
| Sample size | Current accrual: 4 |
| Randomised interventions | Patients will be randomised to receive either Stanford V for 12 weeks, or ABVD for 6-8 cycles, depending on response. |
| Contact details | UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
LONDON NW1 2DA
Tel: +44 (0) 20 7670 4723
Fax: +44 (0) 20 7670 4818
|
| Further information | Further information about this trial may be obtained from UKCCCR Register's own website, which contains full trial reports. |
| General information | Please visit the UKCCCR Register website for further general information. |
| Date live in mRCT | 01 April 2007 |
